COVID-19: Vaccines and Therapeutics
Leaders from the AHA and the American College of Obstetricians and Gynecologists, hospital leaders, clinicians and experts from the Centers for Disease Control and Prevention Jan. 26 will hold a webinar on how health care professionals can work with their patients and communities to build trust in…
A new AHA video is tackling prominent myths about COVID-19 and its vaccines, providing the public with the facts they need to make sound health decisions for themselves and their families.
In addition to the seven new 2022 ICD-10 procedure codes announced in November, the Centers for Medicare & Medicaid Services on April 1 will implement two new ICD-10 procedure codes for reporting COVID-19 therapeutics
The U.S. Supreme Court today allowed the Centers for Medicare & Medicaid Services (CMS) vaccine mandate to go into effect nationwide, while blocking the Occupational Safety and Health Administration’s (OSHA) vaccine requirements from taking effect.
The Food and Drug Administration has revised its provider and recipient fact sheets for the Johnson & Johnson COVID-19 vaccine due to reports of immune thrombocytopenia (ITP), a disorder that can cause easy or excessive bruising and bleeding due to very low platelet levels.
On Jan. 7, the U.S. Supreme Court held oral argument to consider the injunctions that
blocked the Centers for Medicare & Medicaid Services’ (CMS) rule requiring covered
facilities to ensure that their staff are vaccinated against COVID-19 (subject to medical
and religious exemptions).
Details on recent information on treating and preventing COVID-19.
The U.S. Supreme Court today held oral arguments on whether to allow the Centers for Medicare & Medicaid Services’ and Occupational Safety and Health Administration’s vaccine mandates to go into effect while appeals are heard in the courts of appeals.
The Centers for Medicare & Medicaid Services has approved a new Healthcare Common Procedure Coding System code J0248 for the VEKLURY (remdesivir) antiviral medication when administered in an outpatient setting, following a recent statement from the National Institutes of Health COVID-19…
The Food and Drug Administration announced that five months is the recommended interval between a primary dosing regimen and booster for Moderna’s COVID-19 vaccine. Previously, the recommended gap was six months.